In patients with localized prostate cancer, stereotactic body radiotherapy (SBRT) was associated with better urinary continence and sexual function, but slightly worse bowel function, compared with ...

Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said. For patients with low- to intermediate-risk ...

The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Stereotactic body radiotherapy and hormone treatment resulted in 40.1% 12-month progression-free survival in a recent study. Administration of radiotherapy in conjunction with hormone treatment has ...

Five-fraction stereotactic body radiotherapy (SBRT) was found to be noninferior to conventionally or moderately hypofractionated radiotherapy in treating localized prostate cancer, with a 5-year ...

Please provide your email address to receive an email when new articles are posted on . Five-fraction SBRT appeared noninferior to conventional radiotherapy. Grade 2 or higher gastrointestinal adverse ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. The principal investigator of the trial, Ellis is a radiation oncologist and ...